2m 2m 2m 2m 2m 2m 2m
- $55.1MMarket Cap
- 291.78%1-Year Change
- Medical Instruments & SuppliesIndustry
ANBIO-A (NNNN)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 44
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Trump Sparks A 2025 IPO Boom: 5 New Stocks Have Rallied Over 400%
The U.S. IPO market is experiencing a strong revival in 2025, with 163 companies going public and raising $31 billion, driven by a favorable business climate under President Trump's second term and increased investor risk appetite.
10/07/2025, 4:09 PM • Benzinga
Anbio Biotechnology launched a Chikungunya IgM/IgG Rapid Test and an AP-100 Ultra-Fast PCR system to support rapid diagnostic testing for infectious diseases, enabling quick detection of pathogens in both centralized and decentralized healthcare settings.
08/08/2025, 9:05 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Key Executives
- Michael Lau
- Chris Tian
- Suki Song
Current Ownership Distribution
- Other43.8M (99.89%)
- Institutions50,226 (0.11%)
- Mutual Funds0 (0.00%)
- Insiders0 (0.00%)